ClinicalTrials.gg
Active, not recruitingNCT06233591Updated May 15, 2025

Evaluating LP-10 in Subjects With OLP

A Phase 2 interventional study of LP-10 (Liposomal Tacrolimus) in Oral Lichen Planus, sponsored by Lipella Pharmaceuticals, Inc.. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Lipella Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 13 studies in Lichen Planus, Oral with a site in United States — none open to participants now, 1 under way, none of them phase 3. Lichen Planus, Oral · United States.

Planned enrollment
5th of 12
24 · median 24
Started
2024
with 1 other
Phase 2
10 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Lipella Pharmaceuticals, Inc.

Among the 13 studies in Lichen Planus, Oral with a site in United States, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 in phase 2, and was the 12th registered.

Lichen Planus, Oral

142 studies on the registry are indexed under Lichen Planus, Oral; 27 are open to participants now.

Browse Lichen Planus, Oral studies →

Open to participants now

None of the 13 studies in Lichen Planus, Oral with a site in United States is open now. The open studies under Lichen Planus, Oral, anywhere →

Who these studies take

Of the 14 Lichen Planus, Oral studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Lichen Planus, Oral with a site in United States as a file.
02

Study summary

This is a multicenter, dose-ranging study including adult male and female subjects (>= 18 years old) with symptomatic Oral Lichen Planus (OLP). A total of approximately 24 subjects will be enrolled at approximately eight (8) study sites in the United States. This study will evaluate the safety, tolerability and efficacy of LP-10 at 0.25 mg, 0.5 mg and 1.0 mg of tacrolimus.The study consists of screening, treatment and follow-up phases. The treatment phase includes 10 mL LP-10 oral rinse for 3 minutes twice a day for 4 weeks. The follow-up phase includes one post-treatment visit 2 weeks after the last oral LP-10 dose.

03

Conditions studied

  • Oral Lichen Planus

Browse trials for

Keywords

  • OLP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Male or female ≥ 18 years of age
  • Oral performed within the last 10 years before the Screening Visit demonstrating OLP and/or oral lichenoid mucositis in the absence of cancer or dysplasia
  • Moderate OLP based on an OLP Investigator Global Assessment (IGA) score of ≥ 3
  • OLP Pain and Sensitivity Numerical Rating Scale (NRS) score of ≥ 3
  • Patients taking prescription oral or rinse treatment(s) at the time of the Screening Visit agree to stop treatment for the duration of the trial and to undergo a 4-week
  • Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the self-administered questionnaires
  • Willing to avoid while enrolled in the trial
  • Patients of must have a negative pregnancy test and agree to undergo pregnancy testing at each study visit. (unless patient has undergone a bilateral tubal ligation or hysterectomy and/or is as defined by the absence of menses for at least 12 months)
  • Patients of child-bearing potential and male participants with a female partner of child-bearing potential, agree to use a reliable method of (condoms and/or oral contraceptives) for the duration of the trial and for 10 days thereafter

Exclusion criteria

Exclusion Criteria:

  • Hyperkalemia
  • Chronic kidney disease
  • Long syndrome
  • History of oral cavity or oropharyngeal cancers
  • Active cancer
  • Uncontrolled hypertension (i.e., > 145 mm/Hg systolic or > 95 mmHg diastolic)
  • Patients who failed tacrolimus treatment for OLP in the past
  • Patient who is currently or has previously participated in another oral cavity therapeutic or device study within 3 months of screening and has not returned to baseline
  • History of oral cavity infection (bacterial, viral or fungal) within 3 months prior to screening
  • Pregnant or lactating
  • Active bleeding peptic ulcer disease
  • Known allergy to liposomes and/or egg yolk and/or tacrolimus
  • Evidence of renal impairment (creatinine > 2 × the at Visit 1), hepatic impairment ( or ALT > 3 × the upper limit of normal at Visit 1), cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
  • Patients currently taking magnesium and aluminum-hydroxide antacids or metoclopramide
  • Patients currently taking aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, and protease inhibitors
  • The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    LP-10 0.25mg

    0.25mg LP-10 / 10 mL twice daily oral rinse

    Drug: LP-10 (Liposomal Tacrolimus)

  • Experimental
    LP-10 0.5 mg

    0.5mg LP-10 / 10 mL twice daily oral rinse

    Drug: LP-10 (Liposomal Tacrolimus)

  • Experimental
    LP-10 1.0 mg

    1.0mg LP-10 / 10 mL twice daily oral rinse

    Drug: LP-10 (Liposomal Tacrolimus)

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of LP-10 in patients with oral lichen Planus

    Incidence and severity of treatment-emergent adverse events, changes in standard laboratory studies, whole-blood tacrolimus levels

    Time frame: over 4 weeks of treatment and 2 weeks of follow-up

Secondary outcomes

  1. To evaluate the preliminary efficacy of LP-10 in patients with oral lichen planus

    Change in the OLP Investigator Global Assessment (IGA) score

    Time frame: from baseline to 1 and 4 weeks after the first dose and 2 weeks after the last dose

  2. To evaluate the preliminary efficacy of LP-10 in patients with oral lichen planus

    Change in the OLP Reticulation, Erythema, and Ulceration (REU) score

    Time frame: from baseline to 1 and 4 weeks after the first dose and 2 weeks after the last dose

  3. To evaluate the preliminary efficacy of LP-10 in patients with oral lichen planus

    Changes in the Oral Lichen Planus Symptom Severity Measure (OLPSSM) score

    Time frame: from baseline to 1 and 4 weeks after the first dose and 2 weeks after the last dose

  4. To evaluate the preliminary efficacy of LP-10 in patients with oral lichen planus

    Change in the OLP Pain and Sensitivity Numerical Rating Scale (NRS)

    Time frame: from baseline to 1 and 4 weeks after the first dose and 2 weeks after the last dose

  5. To evaluate the preliminary efficacy of LP-10 in patients with oral lichen planus

    Patient Global Response Assessment (GRA)

    Time frame: at 4 weeks after first dose

07

Study locations

7 sites
  • Center for Dermatology
    Fremont, California 94538, United States
  • UCSF School of Dentistry
    San Francisco, California 94143, United States
  • Miami Cancer Institue at Baptist Health, Inc
    Miami, Florida 33176, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Atrium Health Oral Medicine & Maxillofacial Surgery
    Charlotte, North Carolina 28203, United States
  • Paddington Testing Co, Inc
    Philadelphia, Pennsylvania 19103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jun 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 31, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06233591
Lead sponsor
Lipella Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Jul 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
May 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion